002412 Stock Overview
Produces and sells traditional Chinese preparations in China and internationally. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 002412 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Hunan Hansen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥6.36 |
52 Week High | CN¥7.07 |
52 Week Low | CN¥4.08 |
Beta | 0.29 |
1 Month Change | 1.44% |
3 Month Change | 25.94% |
1 Year Change | -4.79% |
3 Year Change | 8.90% |
5 Year Change | -24.82% |
Change since IPO | 0.18% |
Recent News & Updates
Shareholder Returns
002412 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -3.9% | -4.3% | -3.5% |
1Y | -4.8% | -3.4% | 10.9% |
Return vs Industry: 002412 underperformed the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 002412 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
002412 volatility | |
---|---|
002412 Average Weekly Movement | 5.9% |
Pharmaceuticals Industry Average Movement | 7.4% |
Market Average Movement | 8.7% |
10% most volatile stocks in CN Market | 12.8% |
10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002412 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002412's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 1,536 | Zhengqing Liu | www.hansenzy.com |
Hunan Hansen Pharmaceutical Co., Ltd. produces and sells traditional Chinese preparations in China and internationally. It provides medicines in injection, mixture, tablet, capsule, granule, syrup, decoction, tincture, and pill forms. Hunan Hansen Pharmaceutical Co., Ltd.
Hunan Hansen Pharmaceutical Co., Ltd. Fundamentals Summary
002412 fundamental statistics | |
---|---|
Market cap | CN¥3.15b |
Earnings (TTM) | CN¥226.03m |
Revenue (TTM) | CN¥965.37m |
14.2x
P/E Ratio3.3x
P/S RatioIs 002412 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
002412 income statement (TTM) | |
---|---|
Revenue | CN¥965.37m |
Cost of Revenue | CN¥247.47m |
Gross Profit | CN¥717.90m |
Other Expenses | CN¥491.87m |
Earnings | CN¥226.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.45 |
Gross Margin | 74.36% |
Net Profit Margin | 23.41% |
Debt/Equity Ratio | 3.8% |
How did 002412 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/20 13:12 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hunan Hansen Pharmaceutical Co., Ltd. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Yalei Yan | Bohai Securities Co., Ltd. |
Songtao YE | Changjiang Securities Co. LTD. |
Pei Hui Tang | Chasing Securities |